Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026

Cellectis announced final Phase 1 data for lasme-cel, an allogeneic CAR-T therapy targeting CD22 in relapsed/refractory B-cell acute lymphoblastic leukemia, showing 100% overall response rate in the target population with manageable safety profile. The company also presented preliminary data for eti-cel, a dual-targeted CAR-T therapy against CD20 and CD22 in non-Hodgkin lymphoma, demonstrating 88% overall response rate at optimal dose with evidence that alemtuzumab exposure correlates with improved clinical outcomes.